Terminated PHASE2 INTERVENTIONAL 2-arm NCT00573131

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer

Sponsor: Boston Scientific Corporation

Conditions Adenocarcinoma of the Esophagus Esophageal Cancer Squamous Cell Carcinoma

Interventions 5-FU OncoGel (Paclitaxel gel) cisplatin esophageal resection radiation therapy

Updated 10 times since 2017 Last updated: Jun 2, 2022 Started: Jan 31, 2008 Primary completion: Nov 30, 2010 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

OncoGel did not show any impact on overall tumor response

Other terminated trials from Boston Scientific Corporation

More terminations from Boston Scientific Corporation

Other Adenocarcinoma of the Esophagus trials with similar outcome

Browse all Adenocarcinoma of the Esophagus trials

Listed as NCT00573131, this PHASE2 trial focuses on Adenocarcinoma of the Esophagus and Esophageal Cancer and remains terminated or withdrawn. Sponsored by Boston Scientific Corporation, it has been updated 10 times since 2008, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jul 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2022 — Jul 2022 [monthly]

Terminated PHASE2

▶ Show 5 earlier versions

Dec 2021 — Jun 2022 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boston Scientific Corporation

Data source: Boston Scientific Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bangalore, India , Brno, Czechia , Chicago, United States , Dallas, United States , Erandwane, India , Indianapolis, United States , Jablonec nad Nisou, Czechia , Kansas City, United States , Kochi, India , Lublin, Poland and 9 more locations